Business Wire

Amazfit Announces the Bip 6 Smartwatch: The Everyday Smartwatch for Every Moment

31.3.2025 15:00:00 CEST | Business Wire | Press Release

Share

Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), a health technology company, today announced the launch of the Amazfit Bip 6 smartwatch. Featuring a vibrant 1.97-inch AMOLED display, advanced health and heart rate monitoring, AI-powered fitness programs, offline navigation, and comprehensive sleep tracking, the Bip 6 is designed to support everyday fitness enthusiasts at each stage of their health journey.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250331697403/en/

Amazfit introduces Bip 6

Built for everyday durability, the Bip 6 features a sturdy aluminum alloy frame, 5 ATM water resistance, and an impressive two-week battery life. It comes in four stylish colorways—Black, Charcoal, Stone, and Red—all for just $79.99 USD.

“At Amazfit, we believe that technology—especially smart wearables—should enhance every aspect of life without compromising on style, performance, or affordability,” said Wayne Huang, founder & CEO, Zepp Health. “The Bip 6 was meticulously designed for those who need a smartwatch that keeps up with their active lifestyles while looking great. With advanced fitness tracking, intelligent coaching, and dedicated support for HYROX and endurance training, the Bip 6 adapts effortlessly to dynamic lifestyles while offering exceptional value.”

Key Features of the Amazfit Bip 6:

  1. Lightweight Aluminum Design with a Vibrant AMOLED Display
    At 2,000 nits, the Bip 6’s 1.97-inch AMOLED screen is bright and easy to read in all lighting conditions.
  2. Precise Heart Rate & Sleep Data Powered by BioTracker™ Technology
    Equipped with Amazfit’s best-in-class BioTracker™ 6.0 PPG biometric dual-light 5PD heart rate sensor, the Bip 6 offers precise measurements for heart rate, blood oxygen levels, stress monitoring, HRV (heart rate variability) and more.
  3. 140+ Workout Modes Including HYROX Race, Smart Strength Training, and Personalized AI Coaching
    The Bip 6 supports over 140 fitness and lifestyle activities. Its Smart Strength Training feature provides detailed insights, such as automatic grouping of muscle exercises, while offline navigation with round-trip routing is great for outdoor enthusiasts.
  4. Enhanced Battery Life
    With a battery life of up to two weeks and 5 ATM water resistance, the Bip 6 can keep up with even the most active lifestyles.
  5. Smart Features for Everyday Convenience
    Receive on-wrist notifications for calls, texts, social media updates, calendar reminders, and more. Make and answer calls, reply to text messages using voice-to-text and the touch keyboard, control the camera (iPhone only) and music, sync notifications, and more—all through a Bluetooth connection to a phone. Zepp Flow™ provides full voice control of the watch, allowing users to adjust settings, view readiness scores, and more, without tapping, swiping, or memorizing keywords.
  6. The Zepp App: Health and Fitness Tracking with Camera-Powered Food Log
    The updated Zepp App offers a centralized, user-friendly platform for tracking health and fitness data, analyzing trends, and accessing personalized insights - with no mandatory subscriptions. A new food log feature allows users to photograph their meals directly in the app, automatically uploading nutrition data for seamless meal tracking. This feature is currently available in the United States, Canada, Germany, Spain, Italy, France, the UK and Japan.

Availability and Pricing

The Amazfit Bip 6 is available for purchase today on Amazfit.com and Amazon.Priced at $79.99 USD or €79.90 euro, the Bip 6 delivers premium features and performance at an unbeatable value.

For more information, please visit https://www.amazfit.com/en/ and follow us on Facebook, Instagram, X (formerly Twitter) and YouTube.

About Amazfit

Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company. Offering a wide selection of smartwatches and bands, Amazfit's brand tagline "Discover Amazing", encourages individuals to break their barriers, and exceed expectations while finding joy in every moment.

Amazfit is powered by Zepp Health's proprietary health management platform that delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. With outstanding craftsmanship, Amazfit smartwatches have won many design awards, including the iF Design Award and the Red Dot Design Award.

Launched in 2015, Amazfit is today embraced by millions of users. Its products are available in more than 90 countries across the Americas, EMEA, and APAC regions. For more information about Amazfit, visit www.amazfit.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250331697403/en/

Contacts

Media Contact
Mary Woodbury
Head of PR, North America
Mary.woodbury@zepp.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press Release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press Release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press Release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press Release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press Release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye